Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Ridker PM, Devalaraja M, Baeres FMM et al (2021) IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
In its announcement, Novo Nordisk highlighted results from its OASIS 4 clinical program and reported that participants in the OASIS 4 trial achieved a mean 16.6% body-weight reduction over the study period (as described by the company)
Increased Insulin Production: For individuals with type 2 diabetes, Retatrutide offers the added benefit of helping the body produce more insulin, which leads to better control of blood sugar levels
10 DalbgeLSChristensenMMadsenMRSecherTEndlichNDrenicVet al
US$ 24.01
US$ 29.37
US$ 29.49
